Convergent Therapeutics, Inc. — Form D
Convergent Therapeutics, Inc. of CAMBRIDGE, MA, a company, filed a Form D exempt-offering notice with the SEC on 2023-05-22. The offering totals $99.2M, of which $29.2M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2023-05-22
- Form: D
- Accession: 0001978126-23-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $99.2M
- Amount sold: $29.2M
- Remaining: $70.0M
- Investors: 15
- Date of first sale: 2023-04-27
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-482306
Issuer
- Name: Convergent Therapeutics, Inc.
- CIK: 0001978126
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2020
- Address: ONE BROADWAY, CAMBRIDGE, MA, 02142
- Phone: 617-710-4289
Officers, directors & promoters (9)
| Name | Role | Location |
|---|
| Tal Zaks | Director | Watertown, MA |
| Jake Simson | Director | San Mateo, CA |
| Eric Sullivan | Executive Officer | Cambridge, MA |
| Jim Trenkle | Director | Cambridge, MA |
| Philip Kantoff | Director | Cambridge, MA |
| Philip Kantoff | Executive Officer | Cambridge, MA |
| Alexander Brown | Executive Officer | Cambridge, MA |
| Neil Bander | Director | Cambridge, MA |
| Neil Bander | Executive Officer | Cambridge, MA |
Other filings by this issuer (1)
More